N/A N=40 AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study
Walled Off Pancreatic Necrosis
Primary: Number of Participants With Resolution of WON With Endoscopic Drainage — 39 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=67 WallFlex Pancreatic Metal Stent for Pancreatic Duct Strictures
Chronic Pancreatitis
Primary: Pain Reduction — 12 Participants — p=0.999
N/A N=37 EndoRotor DEN (Direct Endoscopic Necrosectomy)Trial
Acute Pancreatic Necrosis · Acute Pancreatitis · Necrotizing Pancreatitis
Primary: Safety: Number of Participants With Device Related Complications — 0 Participants
N/A N=164 WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study
Biliary Stricture
Primary: Number of Participants With Stricture Resolution — 47; 54 Participants — p=.008
N/A N=190 Antibiotic Irrigation for Pancreatoduodenectomy
Surgery · Infection
Primary: The Number of Patients With Infections — 11; 10 Participants
Phase 3 N=168 Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy
Pancreatic Fistula
Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants
N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
N/A N=124 Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections
Surgical Site Infection · Pancreatic Neoplasms · Pancreatic Cancer
Primary: Rate of Surgical Site Infection — 6; 19 Participants — p=0.003
N/A N=14 Pancreatic Endotherapy for Refractory Chronic Pancreatitis
Pancreatic Duct Stone · Pancreatic Duct Stricture · Pancreatic Duct Dilatation
Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change
Phase 2 N=20 Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
Pancreatic Mucinous-Cystic Neoplasm
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants
Phase 1 N=33 Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants
Phase 4 N=43 Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Phase 2 N=20 Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
N/A N=20 Evaluation of Pancreatic Pseudocyst Drainage With a Metal Stent
Pancreatic Pseudocysts
Primary: Technical Success of Endoscopic Ultrasound-guided Single-access Pseudocyst Drainage With a Fully Covered Self-expanding Metal Stent ; Anchored With a Double Pigtail…
N/A N=148 SpHincterotomy for Acute Recurrent Pancreatitis
Pancreatitis · Pancreas Divisum · Pancreatitis, Acute
Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants
Phase 3 N=170 Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
Phase 2 N=60 Fecal Microbiota Transplantation for Pancreatitis
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
Phase 3 N=83 Pentoxifylline Treatment in Acute Pancreatitis (AP)
Acute Pancreatitis (AP) · Gallstone Pancreatitis · Alcoholic Pancreatitis
Primary: Change in C-reactive Protein (C-RP) From Admission Baseline at One Week. — 86.2; 75.8; 116.4; 127.2 mg/L — p=0.5796
N/A N=1 Stereotactic Radiation to Decrease Pancreatic Secretions
Pancreatic Fistulae
Primary: Decreased Secretions — 1 participants
Phase 2 N=54 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
N/A N=529 Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
Infant, Newborn · Infant, Low Birth Weight · Infant, Small for Gestational Age
Primary: Death or Neurodevelopmental Impairment (NDI) — 44; 46; 27; 28 Participants — p=0.03
Phase 3 N=42 A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis
Acute Pancreatitis
Primary: Systemic Inflammatory Response Syndrome (SIRS) Score — -0.96; -1 score on a scale — p=0.87
Phase 2 N=114 A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Pancreatic Leak · Pancreatic Fistula · Pancreaticoduodenal; Fistula
Primary: Combined Clinically Significant Postoperative Pancreatic Fistula and Intra-abdominal Abscess — 8 Participants
Early Phase 1 N=28 Pentoxifylline Treatment of Acute Pancreatitis
Acute Pancreatitis
Primary: Change in C-Reactive Protein (CRP) — 48.4; 60.6; 62; 154 mg/L — p=0.62
N/A N=284 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
Pancreatic Carcinoma
Primary: Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last — 40; 36…
N/A N=36 A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent'
Pancreatic Pseudocyst
Primary: Number of Participants With Clinical Success — 33 participants — p=0.05
Phase 3 N=439 Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Pancreatic Cancer
Primary: To Compare 60-day ≥Grade 3 Pancreatic Complication Rates (Fistula, Leak, and Abscess) as Defined by the MSKCC Surgical Secondary Events System Between Patients Who…
N/A N=174 TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Pancreatic Cancer · Pancreatitis · IPMN
Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78
Phase 2 N=37 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC